TGFB1 and neoplasm: have developed anti-TGF-β/PD-L1 bispecific antibodies (YM101 and BiTP), which activities were superior to anti-TGF-β and anti-PD-L1 monotherapy, they could effectively inhibit TGF-β1-induced Treg differentiation and suppress the proliferation of tumour cells to slow down tumour growth (136, 137).